TY - JOUR T1 - PCSK9 inhibition: A promise fulfilled? JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - S36 LP - S44 DO - 10.3949/ccjm.83.s2.05 VL - 83 IS - 11 suppl 2 AU - Khendi White AU - Chaitra Mohan AU - Michael Rocco Y1 - 2016/11/01 UR - http://www.ccjm.org/content/83/11_suppl_2/S36.abstract N2 - The association of reduced proprotein convertase subtilisin/kexin type 9 (PCSK9) activity with reduced cardiovascular disease (CVD) events—and the need for add-ons to statin therapy to achieve treatment goals— has led to the rapid development and US Food and Drug Administration (FDA) approval of monoclonal antibody therapies to inhibit PCSK9. Now that PCSK9 inhibitors are approved by the FDA for use in certain patients, data from ongoing long-term clinical trials addressing tolerability, safety, and proof of additional reduction in CVD events are eagerly awaited ER -